Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease

Detalhes bibliográficos
Autor(a) principal: Saraiva, Aratã Andrande
Data de Publicação: 2022
Outros Autores: Silva, João Paulo Oliveira da, Sousa, José Vigno Moura, Brandim, Ayrton de Sá
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/37853
Resumo: Currently, there is no drug that has proven neuroprotective properties in Parkinson's disease. The best-known drug is levodopa, which acts as inhibitors of the MAO-B and COMT enzymes involved in dopamine degradation. Although levodopa is the "gold standard" of treatment, as the disease progresses, most patients develop complications from the therapy and side effects. In this sense, the combination of two abundant substances and phytotherapics as alternatives to the use of traditional medicines is approached, namely Zingerone and Gamma-Mangostin. In which they presented favorable results in molecular docking.
id UNIFEI_fa3ff774cf10dc039ebff2c390b822e4
oai_identifier_str oai:ojs.pkp.sfu.ca:article/37853
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s DiseaseAcoplamiento Molecular de Zingerona y Gamma-Mangostin para Inhibir MAO-B y Catecol-O-Metiltransferasa (COMT) en el Tratamiento de la Enfermedad de ParkinsonDocagem Molecular de Zingerone e Gamma-Mangostin para Inibir MAO-B e Catecol-O-Metiltransferase (COMT) no Tratamento da Doença de ParkinsonParkinsonZingeronaGamma-MangostinCatecol-O-Metiltransferasa.ParkinsonZingeroneGamma-MangostinCatecol-O-Metiltransferase.ParkinsonZingeroneGamma-MangostinCatecol-O-Metiltransferase.Currently, there is no drug that has proven neuroprotective properties in Parkinson's disease. The best-known drug is levodopa, which acts as inhibitors of the MAO-B and COMT enzymes involved in dopamine degradation. Although levodopa is the "gold standard" of treatment, as the disease progresses, most patients develop complications from the therapy and side effects. In this sense, the combination of two abundant substances and phytotherapics as alternatives to the use of traditional medicines is approached, namely Zingerone and Gamma-Mangostin. In which they presented favorable results in molecular docking.Actualmente, no existe ningún fármaco que tenga propiedades neuroprotectoras comprobadas en la enfermedad de Parkinson. El fármaco más conocido es la levodopa, que actúa como inhibidor de las enzimas MAO-B y COMT implicadas en la degradación de la dopamina. Aunque la levodopa es el "estándar de oro" del tratamiento, a medida que avanza la enfermedad, la mayoría de los pacientes desarrollan complicaciones a causa de la terapia y los efectos secundarios. En este sentido, se aborda la combinación de dos sustancias abundantes y fitoterapéuticos como alternativas al uso de las medicinas tradicionales, a saber, la Zingerona y la Gamma-Mangostin. En el cual presentaron resultados favorables en acoplamiento molecular.Atualmente, não existe nenhum medicamento que tenha propriedades neuroprotetoras comprovadas na doença de Parkinson. O medicamento mais conhecido é a levedopa que atua como inibidores nas enzimas MAO-B e COMT envolvidas na degradação da dopamina. Apesar da levodopa ser o "padrão ouro" no tratamento, à medida que a doença progride, a maioria dos pacientes desenvolvem complicações da terapia e efeitos colaterais. Neste sentido, é abordado a junção de duas substâncias abundantes e fitoterápicos como alternativas ao uso dos medicamentos tradicionais que é o Zingerone e o Gamma-Mangostin. Nos quais apresentaram resultados favoráveis na docagem molecular.Research, Society and Development2022-12-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3785310.33448/rsd-v11i16.37853Research, Society and Development; Vol. 11 No. 16; e189111637853Research, Society and Development; Vol. 11 Núm. 16; e189111637853Research, Society and Development; v. 11 n. 16; e1891116378532525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/37853/31549Copyright (c) 2022 Aratã Andrande Saraiva; João Paulo Oliveira da Silva; José Vigno Moura Sousa; Ayrton de Sá Brandimhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSaraiva, Aratã Andrande Silva, João Paulo Oliveira da Sousa, José Vigno Moura Brandim, Ayrton de Sá 2022-12-18T18:26:42Zoai:ojs.pkp.sfu.ca:article/37853Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:51:51.529068Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
Acoplamiento Molecular de Zingerona y Gamma-Mangostin para Inhibir MAO-B y Catecol-O-Metiltransferasa (COMT) en el Tratamiento de la Enfermedad de Parkinson
Docagem Molecular de Zingerone e Gamma-Mangostin para Inibir MAO-B e Catecol-O-Metiltransferase (COMT) no Tratamento da Doença de Parkinson
title Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
spellingShingle Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
Saraiva, Aratã Andrande
Parkinson
Zingerona
Gamma-Mangostin
Catecol-O-Metiltransferasa.
Parkinson
Zingerone
Gamma-Mangostin
Catecol-O-Metiltransferase.
Parkinson
Zingerone
Gamma-Mangostin
Catecol-O-Metiltransferase.
title_short Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
title_full Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
title_fullStr Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
title_full_unstemmed Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
title_sort Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
author Saraiva, Aratã Andrande
author_facet Saraiva, Aratã Andrande
Silva, João Paulo Oliveira da
Sousa, José Vigno Moura
Brandim, Ayrton de Sá
author_role author
author2 Silva, João Paulo Oliveira da
Sousa, José Vigno Moura
Brandim, Ayrton de Sá
author2_role author
author
author
dc.contributor.author.fl_str_mv Saraiva, Aratã Andrande
Silva, João Paulo Oliveira da
Sousa, José Vigno Moura
Brandim, Ayrton de Sá
dc.subject.por.fl_str_mv Parkinson
Zingerona
Gamma-Mangostin
Catecol-O-Metiltransferasa.
Parkinson
Zingerone
Gamma-Mangostin
Catecol-O-Metiltransferase.
Parkinson
Zingerone
Gamma-Mangostin
Catecol-O-Metiltransferase.
topic Parkinson
Zingerona
Gamma-Mangostin
Catecol-O-Metiltransferasa.
Parkinson
Zingerone
Gamma-Mangostin
Catecol-O-Metiltransferase.
Parkinson
Zingerone
Gamma-Mangostin
Catecol-O-Metiltransferase.
description Currently, there is no drug that has proven neuroprotective properties in Parkinson's disease. The best-known drug is levodopa, which acts as inhibitors of the MAO-B and COMT enzymes involved in dopamine degradation. Although levodopa is the "gold standard" of treatment, as the disease progresses, most patients develop complications from the therapy and side effects. In this sense, the combination of two abundant substances and phytotherapics as alternatives to the use of traditional medicines is approached, namely Zingerone and Gamma-Mangostin. In which they presented favorable results in molecular docking.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-04
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/37853
10.33448/rsd-v11i16.37853
url https://rsdjournal.org/index.php/rsd/article/view/37853
identifier_str_mv 10.33448/rsd-v11i16.37853
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/37853/31549
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 16; e189111637853
Research, Society and Development; Vol. 11 Núm. 16; e189111637853
Research, Society and Development; v. 11 n. 16; e189111637853
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052799947636736

Registros relacionados